Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel
OBJECTIVE Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral drug resistance is correlated with poor virologic response to new therapy. The International AIDS Society–USA sought to update prior recomme...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2000-05, Vol.283 (18), p.2417-2426 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2426 |
|---|---|
| container_issue | 18 |
| container_start_page | 2417 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 283 |
| creator | Hirsch, Martin S Brun-Vézinet, Françoise D'Aquila, Richard T Hammer, Scott M Johnson, Victoria A Kuritzkes, Daniel R Loveday, Clive Mellors, John W Clotet, Bonaventura Conway, Brian Demeter, Lisa M Vella, Stefano Jacobsen, Donna M Richman, Douglas D |
| description | OBJECTIVE Assays for drug resistance testing in human immunodeficiency virus type
1 (HIV-1) infection are now available and clinical studies suggest that viral
drug resistance is correlated with poor virologic response to new therapy.
The International AIDS Society–USA sought to update prior recommendations
to provide guidance for clinicians regarding indications for HIV-1 resistance
testing. PARTICIPANTS An International AIDS Society–USA 13-member physician panel with
expertise in basic science, clinical research, and patient care involving
HIV resistance to antiretroviral drugs was reconvened to provide recommendations
for the clinical use of drug resistance testing. EVIDENCE AND CONSENSUS PROCESS The full panel met regularly between January and October 1999. Resistance
and resistance testing data appearing in the last decade through April 2000
and presentations at national and international research conferences were
reviewed. Recommendations and considerations were developed by 100% group
consensus, acknowledging that definitive data to support final recommendations
are not yet available. CONCLUSIONS Emerging data indicate that despite limitations, resistance testing
should be incorporated into patient management in some settings. Resistance
testing is recommended to help guide the choice of new regimens after treatment
failure and for guiding therapy for pregnant women. It should be considered
in treatment-naive patients with established infection, but cannot be firmly
recommended in this setting. Testing also should be considered prior to initiating
therapy in patients with acute HIV infection, although therapy should not
be delayed pending the results. Expert interpretation is recommended given
the complexity of results and assay limitations. |
| doi_str_mv | 10.1001/jama.283.18.2417 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71107968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>192692</ama_id><sourcerecordid>71107968</sourcerecordid><originalsourceid>FETCH-LOGICAL-a312t-73bfb876dbf1b6af555520dd47115decd34b0ffa6de821aa8843ad0d4258c76b3</originalsourceid><addsrcrecordid>eNqF0U9rFDEUAPAgFrtW73qRIOJt1rz8mWS8Da22CwXFbb0OmUlSssxkapIRehD8Dn5DP4lpu1Lw4iMQkvx4vPeC0AsgayAE3u30pNdUsTWoNeUgH6EVCKYqJhr1GK0IaVQlueKH6GlKO1ICmHyCDoEoEESJFfrRhuyjzXH-7qMe8UlcrvAXm3zKOgwWX9iUfbjCPuDWLGPGZ5uvFeBNcHbIfg7vCx7mabLB6NtzwrPDOhSQbQx3VyVruznZ4u08eJtvfv_8dblt8Wcd7PgMHTg9Jvt8vx-hy48fLo7PqvNPp5vj9rzSDGiuJOtdr2Rtegd9rZ0oQYkxXAIIYwfDeE-c07WxioLWSnGmDTGcCjXIumdH6O193us4f1tKS93k02DHsRQxL6kreYhsavVfCFLQsuoCX_8Dd_NSGh5TRwEYbwgVBb3ao6WfrOmuo590vOn-jr-AN3ug06BHF8vMfXpwTMias8Je3rPy3Q-PDa0byv4AVYqdIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211349025</pqid></control><display><type>article</type><title>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Hirsch, Martin S ; Brun-Vézinet, Françoise ; D'Aquila, Richard T ; Hammer, Scott M ; Johnson, Victoria A ; Kuritzkes, Daniel R ; Loveday, Clive ; Mellors, John W ; Clotet, Bonaventura ; Conway, Brian ; Demeter, Lisa M ; Vella, Stefano ; Jacobsen, Donna M ; Richman, Douglas D</creator><creatorcontrib>Hirsch, Martin S ; Brun-Vézinet, Françoise ; D'Aquila, Richard T ; Hammer, Scott M ; Johnson, Victoria A ; Kuritzkes, Daniel R ; Loveday, Clive ; Mellors, John W ; Clotet, Bonaventura ; Conway, Brian ; Demeter, Lisa M ; Vella, Stefano ; Jacobsen, Donna M ; Richman, Douglas D</creatorcontrib><description>OBJECTIVE Assays for drug resistance testing in human immunodeficiency virus type
1 (HIV-1) infection are now available and clinical studies suggest that viral
drug resistance is correlated with poor virologic response to new therapy.
The International AIDS Society–USA sought to update prior recommendations
to provide guidance for clinicians regarding indications for HIV-1 resistance
testing. PARTICIPANTS An International AIDS Society–USA 13-member physician panel with
expertise in basic science, clinical research, and patient care involving
HIV resistance to antiretroviral drugs was reconvened to provide recommendations
for the clinical use of drug resistance testing. EVIDENCE AND CONSENSUS PROCESS The full panel met regularly between January and October 1999. Resistance
and resistance testing data appearing in the last decade through April 2000
and presentations at national and international research conferences were
reviewed. Recommendations and considerations were developed by 100% group
consensus, acknowledging that definitive data to support final recommendations
are not yet available. CONCLUSIONS Emerging data indicate that despite limitations, resistance testing
should be incorporated into patient management in some settings. Resistance
testing is recommended to help guide the choice of new regimens after treatment
failure and for guiding therapy for pregnant women. It should be considered
in treatment-naive patients with established infection, but cannot be firmly
recommended in this setting. Testing also should be considered prior to initiating
therapy in patients with acute HIV infection, although therapy should not
be delayed pending the results. Expert interpretation is recommended given
the complexity of results and assay limitations.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.283.18.2417</identifier><identifier>PMID: 10815085</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adult ; AIDS/HIV ; Anti-HIV Agents - pharmacology ; Anti-HIV Agents - therapeutic use ; Biological and medical sciences ; Clinical Trials as Topic ; DNA, Viral - analysis ; Drug resistance ; Drug Resistance, Microbial - genetics ; Drug Therapy, Combination ; Female ; Genotype ; HIV ; HIV Infections - drug therapy ; HIV-1 - drug effects ; HIV-1 - genetics ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Medical sciences ; Microbial Sensitivity Tests ; Phenotype ; Polymerase Chain Reaction ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy ; RNA, Viral - analysis ; Treatment Failure ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Women</subject><ispartof>JAMA : the journal of the American Medical Association, 2000-05, Vol.283 (18), p.2417-2426</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright American Medical Association May 10, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.283.18.2417$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.283.18.2417$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3338,27923,27924,76260,76263</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1357643$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10815085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirsch, Martin S</creatorcontrib><creatorcontrib>Brun-Vézinet, Françoise</creatorcontrib><creatorcontrib>D'Aquila, Richard T</creatorcontrib><creatorcontrib>Hammer, Scott M</creatorcontrib><creatorcontrib>Johnson, Victoria A</creatorcontrib><creatorcontrib>Kuritzkes, Daniel R</creatorcontrib><creatorcontrib>Loveday, Clive</creatorcontrib><creatorcontrib>Mellors, John W</creatorcontrib><creatorcontrib>Clotet, Bonaventura</creatorcontrib><creatorcontrib>Conway, Brian</creatorcontrib><creatorcontrib>Demeter, Lisa M</creatorcontrib><creatorcontrib>Vella, Stefano</creatorcontrib><creatorcontrib>Jacobsen, Donna M</creatorcontrib><creatorcontrib>Richman, Douglas D</creatorcontrib><title>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>OBJECTIVE Assays for drug resistance testing in human immunodeficiency virus type
1 (HIV-1) infection are now available and clinical studies suggest that viral
drug resistance is correlated with poor virologic response to new therapy.
The International AIDS Society–USA sought to update prior recommendations
to provide guidance for clinicians regarding indications for HIV-1 resistance
testing. PARTICIPANTS An International AIDS Society–USA 13-member physician panel with
expertise in basic science, clinical research, and patient care involving
HIV resistance to antiretroviral drugs was reconvened to provide recommendations
for the clinical use of drug resistance testing. EVIDENCE AND CONSENSUS PROCESS The full panel met regularly between January and October 1999. Resistance
and resistance testing data appearing in the last decade through April 2000
and presentations at national and international research conferences were
reviewed. Recommendations and considerations were developed by 100% group
consensus, acknowledging that definitive data to support final recommendations
are not yet available. CONCLUSIONS Emerging data indicate that despite limitations, resistance testing
should be incorporated into patient management in some settings. Resistance
testing is recommended to help guide the choice of new regimens after treatment
failure and for guiding therapy for pregnant women. It should be considered
in treatment-naive patients with established infection, but cannot be firmly
recommended in this setting. Testing also should be considered prior to initiating
therapy in patients with acute HIV infection, although therapy should not
be delayed pending the results. Expert interpretation is recommended given
the complexity of results and assay limitations.</description><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>DNA, Viral - analysis</subject><subject>Drug resistance</subject><subject>Drug Resistance, Microbial - genetics</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Genotype</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Phenotype</subject><subject>Polymerase Chain Reaction</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><subject>RNA, Viral - analysis</subject><subject>Treatment Failure</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Women</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U9rFDEUAPAgFrtW73qRIOJt1rz8mWS8Da22CwXFbb0OmUlSssxkapIRehD8Dn5DP4lpu1Lw4iMQkvx4vPeC0AsgayAE3u30pNdUsTWoNeUgH6EVCKYqJhr1GK0IaVQlueKH6GlKO1ICmHyCDoEoEESJFfrRhuyjzXH-7qMe8UlcrvAXm3zKOgwWX9iUfbjCPuDWLGPGZ5uvFeBNcHbIfg7vCx7mabLB6NtzwrPDOhSQbQx3VyVruznZ4u08eJtvfv_8dblt8Wcd7PgMHTg9Jvt8vx-hy48fLo7PqvNPp5vj9rzSDGiuJOtdr2Rtegd9rZ0oQYkxXAIIYwfDeE-c07WxioLWSnGmDTGcCjXIumdH6O193us4f1tKS93k02DHsRQxL6kreYhsavVfCFLQsuoCX_8Dd_NSGh5TRwEYbwgVBb3ao6WfrOmuo590vOn-jr-AN3ug06BHF8vMfXpwTMias8Je3rPy3Q-PDa0byv4AVYqdIQ</recordid><startdate>20000510</startdate><enddate>20000510</enddate><creator>Hirsch, Martin S</creator><creator>Brun-Vézinet, Françoise</creator><creator>D'Aquila, Richard T</creator><creator>Hammer, Scott M</creator><creator>Johnson, Victoria A</creator><creator>Kuritzkes, Daniel R</creator><creator>Loveday, Clive</creator><creator>Mellors, John W</creator><creator>Clotet, Bonaventura</creator><creator>Conway, Brian</creator><creator>Demeter, Lisa M</creator><creator>Vella, Stefano</creator><creator>Jacobsen, Donna M</creator><creator>Richman, Douglas D</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20000510</creationdate><title>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel</title><author>Hirsch, Martin S ; Brun-Vézinet, Françoise ; D'Aquila, Richard T ; Hammer, Scott M ; Johnson, Victoria A ; Kuritzkes, Daniel R ; Loveday, Clive ; Mellors, John W ; Clotet, Bonaventura ; Conway, Brian ; Demeter, Lisa M ; Vella, Stefano ; Jacobsen, Donna M ; Richman, Douglas D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a312t-73bfb876dbf1b6af555520dd47115decd34b0ffa6de821aa8843ad0d4258c76b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>DNA, Viral - analysis</topic><topic>Drug resistance</topic><topic>Drug Resistance, Microbial - genetics</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Genotype</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Phenotype</topic><topic>Polymerase Chain Reaction</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><topic>RNA, Viral - analysis</topic><topic>Treatment Failure</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirsch, Martin S</creatorcontrib><creatorcontrib>Brun-Vézinet, Françoise</creatorcontrib><creatorcontrib>D'Aquila, Richard T</creatorcontrib><creatorcontrib>Hammer, Scott M</creatorcontrib><creatorcontrib>Johnson, Victoria A</creatorcontrib><creatorcontrib>Kuritzkes, Daniel R</creatorcontrib><creatorcontrib>Loveday, Clive</creatorcontrib><creatorcontrib>Mellors, John W</creatorcontrib><creatorcontrib>Clotet, Bonaventura</creatorcontrib><creatorcontrib>Conway, Brian</creatorcontrib><creatorcontrib>Demeter, Lisa M</creatorcontrib><creatorcontrib>Vella, Stefano</creatorcontrib><creatorcontrib>Jacobsen, Donna M</creatorcontrib><creatorcontrib>Richman, Douglas D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirsch, Martin S</au><au>Brun-Vézinet, Françoise</au><au>D'Aquila, Richard T</au><au>Hammer, Scott M</au><au>Johnson, Victoria A</au><au>Kuritzkes, Daniel R</au><au>Loveday, Clive</au><au>Mellors, John W</au><au>Clotet, Bonaventura</au><au>Conway, Brian</au><au>Demeter, Lisa M</au><au>Vella, Stefano</au><au>Jacobsen, Donna M</au><au>Richman, Douglas D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2000-05-10</date><risdate>2000</risdate><volume>283</volume><issue>18</issue><spage>2417</spage><epage>2426</epage><pages>2417-2426</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>OBJECTIVE Assays for drug resistance testing in human immunodeficiency virus type
1 (HIV-1) infection are now available and clinical studies suggest that viral
drug resistance is correlated with poor virologic response to new therapy.
The International AIDS Society–USA sought to update prior recommendations
to provide guidance for clinicians regarding indications for HIV-1 resistance
testing. PARTICIPANTS An International AIDS Society–USA 13-member physician panel with
expertise in basic science, clinical research, and patient care involving
HIV resistance to antiretroviral drugs was reconvened to provide recommendations
for the clinical use of drug resistance testing. EVIDENCE AND CONSENSUS PROCESS The full panel met regularly between January and October 1999. Resistance
and resistance testing data appearing in the last decade through April 2000
and presentations at national and international research conferences were
reviewed. Recommendations and considerations were developed by 100% group
consensus, acknowledging that definitive data to support final recommendations
are not yet available. CONCLUSIONS Emerging data indicate that despite limitations, resistance testing
should be incorporated into patient management in some settings. Resistance
testing is recommended to help guide the choice of new regimens after treatment
failure and for guiding therapy for pregnant women. It should be considered
in treatment-naive patients with established infection, but cannot be firmly
recommended in this setting. Testing also should be considered prior to initiating
therapy in patients with acute HIV infection, although therapy should not
be delayed pending the results. Expert interpretation is recommended given
the complexity of results and assay limitations.</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>10815085</pmid><doi>10.1001/jama.283.18.2417</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2000-05, Vol.283 (18), p.2417-2426 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71107968 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Adult AIDS/HIV Anti-HIV Agents - pharmacology Anti-HIV Agents - therapeutic use Biological and medical sciences Clinical Trials as Topic DNA, Viral - analysis Drug resistance Drug Resistance, Microbial - genetics Drug Therapy, Combination Female Genotype HIV HIV Infections - drug therapy HIV-1 - drug effects HIV-1 - genetics Human immunodeficiency virus Human viral diseases Humans Infectious diseases Medical sciences Microbial Sensitivity Tests Phenotype Polymerase Chain Reaction Pregnancy Pregnancy Complications, Infectious - drug therapy RNA, Viral - analysis Treatment Failure Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Women |
| title | Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T05%3A52%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiretroviral%20Drug%20Resistance%20Testing%20in%20Adult%20HIV-1%20Infection:%20Recommendations%20of%20an%20International%20AIDS%20Society%E2%80%93USA%20Panel&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Hirsch,%20Martin%20S&rft.date=2000-05-10&rft.volume=283&rft.issue=18&rft.spage=2417&rft.epage=2426&rft.pages=2417-2426&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.283.18.2417&rft_dat=%3Cproquest_pubme%3E71107968%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211349025&rft_id=info:pmid/10815085&rft_ama_id=192692&rfr_iscdi=true |